{"product_id":"ikna-vrio-analysis","title":"Ikena Oncology, Inc. (IKNA): VRIO Analysis [Mar-2026 Updated]","description":"\u003cbr\u003e\u003cp\u003eUnlocking the sustainable competitive advantage of Ikena Oncology, Inc. (IKNA) hinges on a rigorous VRIO assessment. Dive into the distilled findings below (\u0026amp;O4\u0026amp;) to see precisely how its resources stack up against the tests of Value, Rarity, Inimitability, and Organization - and learn what this means for its long-term market dominance.\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eIkena Oncology, Inc. (IKNA) - VRIO Analysis: \u003cstrong\u003e1. Global Rights to IK-175 and IK-412 Programs\u003c\/strong\u003e\n\u003c\/h2\u003e\n\u003cp\u003eYou’re looking at the residual value of Ikena Oncology’s pre-merger pipeline assets following the July 2025 merger with Inmagene Biopharmaceuticals. The core question here is whether holding the global rights to IK-175 (an AHR antagonist) and IK-412 (a Kynase degrader) offers a competitive edge to the newly formed entity, even though both were previously discontinued after Bristol Myers Squibb handed back rights in January 2024. The value is certainly latent, sitting on the books as optionality.\u003c\/p\u003e\n\n\u003cp\u003eThe premise is that the combined company, now focused on Inmagene’s IMG-007, has somehow regained or retained these rights, which target immunosuppressive pathways like AhR. If true, this provides a potential upside if the leadership decides to re-prioritize these specific oncology targets later on. To be fair, the underlying science and data package supporting these differentiated targets are not easily replicated overnight, which speaks to rarity, even if the assets are currently dormant.\u003c\/p\u003e\n\n\u003cp\u003eHere’s the quick math on the financial context as of mid-2025: As of June 30, 2025, the company carried an accumulated deficit of $343.0 million, and net losses for the first half of 2025 were $11.4 million. This cash burn environment suggests that non-core assets like these rights are unlikely to see immediate investment. The organization’s structure, post-merger, is clearly centered on Inmagene’s pipeline, making the retention of these rights a strategic choice for future optionality, not near-term focus.\u003c\/p\u003e\n\n\u003cp\u003eThe structure for asset monetization is the Contingent Value Rights (CVR) agreement, effective around July 24, 2025. This means any future proceeds from dispositions of pre-Merger assets, including potential milestone or royalty payments from these rights, would flow to the CVR holders, not directly to the operating budget for new development. This setup reinforces the idea that the value is externalized and temporary.\u003c\/p\u003e\n\n\u003cp\u003eThe VRIO assessment for these specific rights, based on the current strategic pivot, looks like this:\u003c\/p\u003e\n\n\u003ctable\u003e\n  \u003ctr\u003e\n    \u003cth\u003eVRIO Dimension\u003c\/th\u003e\n    \u003cth\u003eAssessment for IK-175\/IK-412 Rights\u003c\/th\u003e\n    \u003cth\u003eJustification\u003c\/th\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003e\u003cstrong\u003eValue (V)\u003c\/strong\u003e\u003c\/td\u003e\n    \u003ctd\u003ePotentially Valuable (Latent)\u003c\/td\u003e\n    \u003ctd\u003eRegaining rights offers optionality for future oncology focus, but they are not currently driving revenue or active development.\u003c\/td\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003e\u003cstrong\u003eRarity (R)\u003c\/strong\u003e\u003c\/td\u003e\n    \u003ctd\u003eRare\u003c\/td\u003e\n    \u003ctd\u003eOwning 100% of the specific, differentiated science for AhR modulation is uncommon in the current crowded oncology space.\u003c\/td\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003e\u003cstrong\u003eImitability (I)\u003c\/strong\u003e\u003c\/td\u003e\n    \u003ctd\u003eDifficult to Imitate (Science)\u003c\/td\u003e\n    \u003ctd\u003eThe historical data package and underlying biological understanding are hard to copy quickly, though the assets are inactive.\u003c\/td\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003e\u003cstrong\u003eOrganization (O)\u003c\/strong\u003e\u003c\/td\u003e\n    \u003ctd\u003eOrganized for Divestiture\/Optionality\u003c\/td\u003e\n    \u003ctd\u003eThe organization is structured around the merger focus, but the CVR mechanism shows intent to capture value if these assets are later sold or licensed.\u003c\/td\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003e\u003cstrong\u003eCompetitive Advantage\u003c\/strong\u003e\u003c\/td\u003e\n    \u003ctd\u003eTemporary Competitive Advantage\u003c\/td\u003e\n    \u003ctd\u003eThe advantage is conditional; it only materializes if the ImageneBio leadership decides to re-invest or successfully monetize the rights before the CVR window closes.\u003c\/td\u003e\n  \u003c\/tr\u003e\n\u003c\/table\u003e\n\n\u003cp\u003eThe fact that Ikena had already sold other assets\/out-licensed tech for up-front payments totaling $1.9 million through June 30, 2025, shows a pattern of monetizing non-core IP, which is the most likely near-term outcome for these rights, rather than re-activation.\u003c\/p\u003e\n\n\u003cp\u003eThe key takeaways on the status of these specific assets are:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eIK-175 and IK-412 were discontinued in January 2024.\u003c\/li\u003e\n\u003cli\u003eThe prior collaboration partner, Bristol Myers Squibb, handed back rights.\u003c\/li\u003e\n\u003cli\u003eThe current focus is on IMG-007 post-merger.\u003c\/li\u003e\n\u003cli\u003eAny realized value from these assets is likely channeled through the CVR structure.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eIf onboarding takes 14+ days to formally assess the IP transfer status post-merger, churn risk rises for any potential internal champion for these legacy assets.\u003c\/p\u003e\n\u003cp\u003eFinance: draft 13-week cash view by Friday.\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eIkena Oncology, Inc. (IKNA) - VRIO Analysis: \u003cstrong\u003e2. Strategic Access to Growth Capital via PIPE Financing\u003c\/strong\u003e\n\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e The concurrent \\$75.0 million private placement (PIPE) provided essential, non-dilutive cash to the combined entity immediately following the merger closing on July 25, 2025. The total capital available to support the development of IMG-007 was approximately \\$175 million. The post-merger entity, ImageneBio, reported \\$142.6 million in cash and cash equivalents and marketable securities as of September 30, 2025.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e Securing a significant, late-stage financing round alongside a complex merger is difficult, especially for a company with a winding-down pipeline (Ikena's pre-merger focus).\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e The syndicate of sophisticated investors is hard to replicate without a proven track record or a compelling asset.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e The finance team successfully executed a complex financing structure, demonstrating capability in capital markets engagement.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e Temporary; this cash provides a runway, but the advantage fades as the funds are spent.\u003c\/p\u003e\n\u003cp\u003eThe structure and participants of the financing are detailed below:\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003ctd\u003eMetric\u003c\/td\u003e\n\u003ctd\u003eValue\/Detail\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eFinancing Amount\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e\\$75.0 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eClosing Date\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003eJuly 25, 2025\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTotal Post-Transaction Capital\u003c\/td\u003e\n\u003ctd\u003eApproximately \u003cstrong\u003e\\$175 million\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePost-Financing Cash (as of 9\/30\/2025)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e\\$142.6 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCombined Entity Post-Financing Ownership (Fully Diluted)\u003c\/td\u003e\n\u003ctd\u003ePIPE Investors: \u003cstrong\u003e21.6%\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003eThe investor syndicate included:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cstrong\u003eNew Investors:\u003c\/strong\u003e Deep Track Capital, Foresite Capital, and RTW Investments.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eExisting Ikena Investors:\u003c\/strong\u003e BVF Partners L.P., Blue Owl Healthcare Opportunities, Omega Funds, and OrbiMed.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eThe ownership breakdown immediately following the closing of the merger and concurrent financing on a fully diluted basis was:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eLegacy Inmagene equity holders: approximately \u003cstrong\u003e43.1%\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eLegacy Ikena equity holders: approximately \u003cstrong\u003e35.3%\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eInvestors in the concurrent financing: approximately \u003cstrong\u003e21.6%\u003c\/strong\u003e.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cbr\u003e\u003ch2\u003eIkena Oncology, Inc. (IKNA) - VRIO Analysis: \u003cstrong\u003e3. Expertise in Precision Oncology Drug Development\u003c\/strong\u003e\n\u003c\/h2\u003e\n\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e The institutional knowledge and specialized team that designed and advanced targeted small molecule inhibitors, like the MEK-RAF molecular glue IK-595, is a key human capital asset.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e Deep, focused expertise in specific, novel mechanisms like molecular glues or pathway inhibition is not common across all biotech firms.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e This is high-quality tacit knowledge, built over years, making it difficult for competitors to imitate quickly.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e The organization was streamlined in 2024\/2025 to focus this talent on clinical execution, showing a clear organizational alignment around this skill.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e Sustained; human capital and specialized know-how are durable advantages in R\u0026amp;D.\u003c\/p\u003e\n\n\u003cp\u003eThe organizational alignment in 2024\/2025 demonstrates a strategic commitment to leveraging the existing expertise in the RAS pathway, evidenced by the prioritization of IK-595 and the discontinuation of IK-930.\u003c\/p\u003e\n\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eData Point\u003c\/th\u003e\n\u003cth\u003eDate\/Period\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eCash Position (End of Period)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$175 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eDecember 31, 2023\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCash Position (End of Period)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$157.3 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eMarch 31, 2024\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eProjected Cash Runway\u003c\/td\u003e\n\u003ctd\u003eInto \u003cstrong\u003e2H 2026\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003ctd\u003eAs of January\/May 2024\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eWorkforce Reduction (Initial)\u003c\/td\u003e\n\u003ctd\u003eApproximately \u003cstrong\u003e35%\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003ctd\u003eQ1 2024\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eWorkforce Reduction (Subsequent)\u003c\/td\u003e\n\u003ctd\u003eApproximately \u003cstrong\u003e53%\u003c\/strong\u003e (approx. \u003cstrong\u003e18\u003c\/strong\u003e employees)\u003c\/td\u003e\n\u003ctd\u003eBy end of Q3 2024\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRestructuring Cost (Subsequent)\u003c\/td\u003e\n\u003ctd\u003eApproximately \u003cstrong\u003e$1.2 million\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003ctd\u003eProjected\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eIK-595 pERK Inhibition (4 hours)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e80%\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003ePhase I Data\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eIK-595 pERK Inhibition (24 hours)\u003c\/td\u003e\n\u003ctd\u003eOver \u003cstrong\u003e60%\u003c\/strong\u003e maintained\u003c\/td\u003e\n\u003ctd\u003ePhase I Data\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\n\u003cp\u003eThe core expertise is demonstrated through the successful advancement and initial data readouts of the lead asset, IK-595, a MEK-RAF molecular glue:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eIK-595 first cohort treated and cleared safety evaluation window in December 2023.\u003c\/li\u003e\n\u003cli\u003eEnrollment of targeted RAS and RAF mutant cancer patients in dose escalation continues.\u003c\/li\u003e\n\u003cli\u003eThe drug targets the RAS signaling pathway by trapping MEK and RAF in an inactive complex.\u003c\/li\u003e\n\u003cli\u003eThe company's strategy involved a reallocation of resources from exploratory discovery to the clinical development of IK-595 and IK-930 in January 2024.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eThe organizational focus post-restructuring in 2024 was exclusively on the clinical execution for IK-595, indicating a high-value placement of specialized personnel.\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eIkena Oncology, Inc. (IKNA) - VRIO Analysis: \u003cstrong\u003e4. Successful Asset Monetization Track Record\u003c\/strong\u003e\n\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003eValue\u003c\/strong\u003e: The company successfully sold assets and out-licensed technologies for up-front payments totaling \u003cstrong\u003e$1.9 million\u003c\/strong\u003e through June 30, 2025, generating non-dilutive cash.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eRarity\u003c\/strong\u003e: Many early-stage biotechs struggle to monetize non-core IP; this demonstrates transactional success.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eImitability\u003c\/strong\u003e: The specific deal terms are unique, but the ability to structure and close such deals is a repeatable skill.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOrganization\u003c\/strong\u003e: This required a dedicated strategic review process, which was clearly in place as they explored strategic options.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage\u003c\/strong\u003e: Temporary; this advantage is tied to the existence of remaining non-core IP to sell.\u003c\/p\u003e\n\u003cp\u003eThe track record of monetization, even if modest in aggregate, is evidenced by specific transactional activities:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eThe Bristol-Myers Squibb Collaboration Agreement, which included programs IK-175 and IK-412, was completed in January 2024, resulting in \u003cstrong\u003e$0\u003c\/strong\u003e collaboration revenue for the three months ended March 31, 2024, compared to \u003cstrong\u003e$5.3 million\u003c\/strong\u003e for the same period in 2023.\u003c\/li\u003e\n\u003cli\u003eThe company reported cash, cash equivalents, and marketable securities of \u003cstrong\u003e$157.3 million\u003c\/strong\u003e as of March 31, 2024.\u003c\/li\u003e\n\u003cli\u003eA concurrent private placement of \u003cstrong\u003e$75.0 million\u003c\/strong\u003e was completed on July 25, 2025, at the time of the merger with Inmagene Biopharmaceuticals.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eThe specific monetization events contributing to the cumulative figure are summarized below:\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eMonetization Event Type\u003c\/th\u003e\n\u003cth\u003eUp-front Payment (Millions USD)\u003c\/th\u003e\n\u003cth\u003eDate Reference Point\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eAsset Sale\/Out-license (Cumulative)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$1.9\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eThrough June 30, 2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eBristol-Myers Squibb Collaboration (Prior Revenue)\u003c\/td\u003e\n\u003ctd\u003eReported \u003cstrong\u003e$5.3 million\u003c\/strong\u003e in Q1 2023\u003c\/td\u003e\n\u003ctd\u003eQ1 2023\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\n\u003cbr\u003e\u003ch2\u003eIkena Oncology, Inc. (IKNA) - VRIO Analysis: \u003cstrong\u003e5. The Winding-Down IK-595 Clinical Program Data\u003c\/strong\u003e\n\u003c\/h2\u003e\n\u003cp\u003eThe analysis below is based on data reported as of January 6, 2025, for the Phase 1 study (NCT06270082) of IK-595.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e Despite the strategic pivot away from other assets, the Phase 1 data generated for IK-595 provides clinical proof-of-concept data for this MEK-RAF molecular glue mechanism.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e Having human data on a novel molecular glue targeting RAS\/RAF mutations is rare, even if the program's strategic focus shifts.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e Competitors cannot easily replicate the specific patient data generated from Ikena’s first-in-human study.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e The organizational structure showed responsiveness by continuing IK-595 development while discontinuing IK-930 development in May 2024, which was accompanied by a workforce reduction of approximately \u003cstrong\u003e53%\u003c\/strong\u003e.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e Temporary; the data's shelf life and relevance will diminish as newer data emerges from competitors.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eIK-595 Phase 1 Dose Escalation Data Summary (As of Jan 06, 2025)\u003c\/strong\u003e\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003ePts Enrolled (Dose Escalation)\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e51\u003c\/strong\u003e pts\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDose Regimens Tested\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e8\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDose Range Administered\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e0.5-8 mg\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRAS Mutation Frequency\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e88%\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRAF Mutation Frequency\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e12%\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMedian Prior Lines of Therapy\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e3\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePrimary Diagnosis: CRC\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e53%\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePrimary Diagnosis: Pancreatic Cancer\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e23.5%\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOverall Disease Control Rate (DCR)\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e44% (15\/34)\u003c\/strong\u003e in disease-evaluable pts\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eConfirmed Partial Responses (cPRs)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e2\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eUnconfirmed Partial Response (uPR)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e1\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eLongest Stable Disease (SD) Duration\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e30 weeks\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\n\u003cp\u003e\u003cstrong\u003ePharmacodynamic (PD) Inhibition Data\u003c\/strong\u003e\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eSaturating pERK inhibition occurred with doses $\\ge$\u003cstrong\u003e1 mg\u003c\/strong\u003e at \u003cstrong\u003e4 hrs\u003c\/strong\u003e after dosing.\u003c\/li\u003e\n\u003cli\u003eThe \u003cstrong\u003e6 mg\u003c\/strong\u003e dose resulted in a PD response of $\\sim$\u003cstrong\u003e90%\u003c\/strong\u003e at \u003cstrong\u003e24 hrs\u003c\/strong\u003e and $\\sim$\u003cstrong\u003e80%\u003c\/strong\u003e at \u003cstrong\u003e72 hrs\u003c\/strong\u003e.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003e\u003cstrong\u003eFinancial and Organizational Context (As of Q1 2024\/May 2024 Announcements)\u003c\/strong\u003e\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eCash, cash equivalents, and marketable securities as of March 31, 2024: \u003cstrong\u003e$157.3 million\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eWorkforce reduction executed in May 2024: Approximately \u003cstrong\u003e53%\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eIK-595 Phase 1 Study Start Date: \u003cstrong\u003eDecember 2023\u003c\/strong\u003e.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cbr\u003e\u003ch2\u003eIkena Oncology, Inc. (IKNA) - VRIO Analysis: \u003cstrong\u003e6. Intellectual Property Rights to Legacy Targets\u003c\/strong\u003e\n\u003c\/h2\u003e\n\u003cp\u003e\n\u003ch\u003eValue: The portfolio of patents and proprietary data covering the Hippo pathway (IK-930) and other targets provides a defensive moat around past R\u0026amp;D investment.\u003c\/h\u003e\n\u003c\/p\u003e\u003cp\u003eThe Hippo pathway is genetically altered in approximately 10% of all human cancers. In epithelioid hemangioendothelioma (EHE), this figure is as high as 100%. The lead asset, IK-930, was a TEAD1 selective inhibitor. As of March 31, 2024, the company reported $157.3 million in cash, cash equivalents, and marketable securities.\u003c\/p\u003e\n\u003ch\u003eRarity: A portfolio of granted patents in novel oncology targets is inherently rare, even if the lead candidates are discontinued.\u003c\/h\u003e\n\u003cp\u003eThe portfolio included patents covering the Hippo pathway (IK-930), an AHR signaling molecule (IK-175), and a Kynurenine degrader (IK-412).\u003c\/p\u003e\n\u003ch\u003eImitability: Patents are legally protected, making the core IP difficult to imitate until they expire.\u003c\/h\u003e\n\u003cp\u003eThe legal protection offered by patents serves as a barrier until expiration, irrespective of the clinical status of the lead candidate.\u003c\/p\u003e\n\u003ch\u003eOrganization: The legal and IP management function successfully protected these rights through the merger and asset sales.\u003c\/h\u003e\n\u003cp\u003eIkena shareholders are entitled to Contingent Value Rights (CVRs) for Ikena's legacy pipeline assets following the merger agreement. The company executed a workforce reduction of approximately 53% in connection with the winddown of the IK-930 program.\u003c\/p\u003e\n\u003ch\u003eCompetitive Advantage: Sustained; patent protection offers a long-term, legally enforced barrier.\u003c\/h\u003e\n\u003cp\u003eThe legal enforceability of the IP provides a sustained barrier until patent expiry.\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003ctd\u003eLegacy Target\/Asset\u003c\/td\u003e\n\u003ctd\u003eMechanism\/Pathway\u003c\/td\u003e\n\u003ctd\u003eStatus (as of May 2024)\u003c\/td\u003e\n\u003ctd\u003eFinancial Context Note\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eIK-930\u003c\/td\u003e\n\u003ctd\u003eTEAD1-selective Hippo pathway inhibitor\u003c\/td\u003e\n\u003ctd\u003eDiscontinued (May 2024)\u003c\/td\u003e\n\u003ctd\u003eInitial data showed clinical activity in EHE.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eIK-175\u003c\/td\u003e\n\u003ctd\u003eAHR inhibitor\u003c\/td\u003e\n\u003ctd\u003eDiscontinued (Jan 2024)\u003c\/td\u003e\n\u003ctd\u003eBMS handed back rights.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eIK-412\u003c\/td\u003e\n\u003ctd\u003eKynurenine degrader\u003c\/td\u003e\n\u003ctd\u003eDiscontinued (Jan 2024)\u003c\/td\u003e\n\u003ctd\u003eBMS handed back rights.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003eThe legacy IP rights are structured to potentially yield future value through CVRs tied to disposition agreements.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eIK-930 targeted TEAD transcription factors.\u003c\/li\u003e\n\u003cli\u003eIK-930 selectivity was for TEAD1 over TEAD2, 3, or 4.\u003c\/li\u003e\n\u003cli\u003ePreclinical models showed IK-930 was a potent inhibitor of TEAD and ensuing gene expression.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cbr\u003e\u003ch2\u003eIkena Oncology, Inc. (IKNA) - VRIO Analysis: \u003cstrong\u003e7. Corporate Restructuring and Reverse Stock Split Execution\u003c\/strong\u003e\n\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e Successfully executing a \u003cstrong\u003e1-for-12\u003c\/strong\u003e reverse stock split prior to the July \u003cstrong\u003e25, 2025\u003c\/strong\u003e merger closing ensured the combined company met Nasdaq listing requirements under the new ticker \u003cstrong\u003eIMA\u003c\/strong\u003e. The action reduced issued and outstanding shares from approximately \u003cstrong\u003e48.2 million\u003c\/strong\u003e to approximately \u003cstrong\u003e4 million\u003c\/strong\u003e.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e Successfully navigating a complex reverse split immediately preceding a major transaction is a specific, high-stakes operational feat.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e The process itself is procedural, but the flawless execution under pressure is hard to copy.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e This demonstrates high-level corporate governance and operational execution capability under extreme time constraints.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e Temporary; this is a one-time corporate action, not an ongoing operational advantage.\u003c\/p\u003e\n\u003cp\u003eThe corporate restructuring involved several quantifiable elements:\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003ctd\u003eMetric\u003c\/td\u003e\n\u003ctd\u003ePre-Action\/Pre-Split Value\u003c\/td\u003e\n\u003ctd\u003ePost-Action\/Post-Split Value\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eStock Split Ratio\u003c\/td\u003e\n\u003ctd\u003eN\/A\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e1-for-12\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eIssued and Outstanding Shares (Approximate)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e48.2 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e4 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eEffective Date of Split Trading\u003c\/td\u003e\n\u003ctd\u003eN\/A\u003c\/td\u003e\n\u003ctd\u003eJuly \u003cstrong\u003e28, 2025\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePar Value Per Share\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$0.001\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$0.001\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNew CUSIP Number\u003c\/td\u003e\n\u003ctd\u003eN\/A (Old CUSIP not specified)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e45175G207\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003eThe execution was concurrent with significant financial and structural changes:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eThe reverse stock split preceded the closing of the merger with Inmagene Biopharmaceuticals on July \u003cstrong\u003e25, 2025\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eThe combined entity, ImageneBio, Inc., commenced trading under ticker \u003cstrong\u003eIMA\u003c\/strong\u003e on July \u003cstrong\u003e28, 2025\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eThe transaction included a concurrent private placement financing totaling \u003cstrong\u003e$75.0 million\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eThe pre-merger valuation of Ikena Oncology was reported at approximately \u003cstrong\u003e$64.52 million\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003ePost-merger ownership allocation was reported as \u003cstrong\u003e43.1%\u003c\/strong\u003e to Inmagene shareholders, \u003cstrong\u003e35.3%\u003c\/strong\u003e to Ikena shareholders, and \u003cstrong\u003e21.6%\u003c\/strong\u003e to new investors.\u003c\/li\u003e\n\u003cli\u003eThe post-merger outstanding share count was reported as approximately \u003cstrong\u003e11.6 million\u003c\/strong\u003e shares of common stock.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cbr\u003e\u003ch2\u003eIkena Oncology, Inc. (IKNA) - VRIO Analysis: \u003cstrong\u003e8. Contingent Value Rights (CVRs) Structure\u003c\/strong\u003e\n\u003c\/h2\u003e\n\u003cp\u003eThe CVR structure is a direct result of the merger agreement with Inmagene Biopharmaceuticals, which closed on \u003cstrong\u003eJuly 25, 2025\u003c\/strong\u003e.\u003c\/p\u003e\n\n\u003ch3\u003eValue\u003c\/h3\u003e\n\u003cp\u003eThe creation of CVRs for Ikena shareholders tied to the legacy pipeline assets provides a mechanism to share future risk\/reward, potentially smoothing the transition for former investors.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eOne \u003cstrong\u003eCVR\u003c\/strong\u003e was issued for each outstanding share of Ikena common stock held by stockholders of record as of the close of business on \u003cstrong\u003eJuly 24, 2025\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eThe CVRs are a \u003cstrong\u003eone-time special dividend\u003c\/strong\u003e.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch3\u003eRarity\u003c\/h3\u003e\n\u003cp\u003eCVRs are not standard in every merger; this specific financial engineering is a unique feature of the deal.\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eCVR Feature\u003c\/th\u003e\n\u003cth\u003eDetail\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eTransferability\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003eNot transferable\u003c\/strong\u003e, except in limited circumstances.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eVoting\/Dividend Rights\u003c\/td\u003e\n\u003ctd\u003eCVRs have \u003cstrong\u003eno voting or dividend rights\u003c\/strong\u003e.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eInterest Accrual\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003eNo interest\u003c\/strong\u003e will accrue on any amounts payable in respect of the CVRs.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\n\u003ch3\u003eImitability\u003c\/h3\u003e\n\u003cp\u003eThe specific CVR terms are unique to this transaction and cannot be easily copied by others.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eThe CVRs do not represent any \u003cstrong\u003eequity or ownership interest\u003c\/strong\u003e in the Company or any of its affiliates.\u003c\/li\u003e\n\u003cli\u003eThe right to contingent payments is a \u003cstrong\u003econtractual right only\u003c\/strong\u003e.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch3\u003eOrganization\u003c\/h3\u003e\n\u003cp\u003eThis required sophisticated legal and financial structuring, showing a high degree of deal-making sophistication.\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eDisposition Agreement Timing\u003c\/th\u003e\n\u003cth\u003eCVR Holder Net Proceeds Percentage\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eEntered into \u003cstrong\u003eprior to the Closing Date\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e100%\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eEntered into \u003cstrong\u003eafter the Closing Date and prior to the first anniversary\u003c\/strong\u003e of Closing\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e90%\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003ePermitted deductions from net proceeds include applicable tax payments, certain expenses incurred by Ikena or its affiliates, and losses from third-party proceedings or wind-down costs.\u003c\/p\u003e\n\n\u003ch3\u003eCompetitive Advantage\u003c\/h3\u003e\n\u003cp\u003eTemporary; the advantage is purely financial and time-bound by the CVR terms.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eThe CVRs are tied to disposition agreements related to Ikena's pre-Merger assets, including the specific asset \u003cstrong\u003eIK-595\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eThe CVR Term dictates the period for potential proceeds; in the event \u003cstrong\u003eno such proceeds are received\u003c\/strong\u003e during the term, holders will receive \u003cstrong\u003eno payment\u003c\/strong\u003e.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cbr\u003e\u003ch2\u003eIkena Oncology, Inc. (IKNA) - VRIO Analysis: \u003cstrong\u003e9. Financial Health as of Q1 2025 (Pre-Merger Snapshot)\u003c\/strong\u003e\n\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e The Q1 2025 net loss of \u003cstrong\u003e\\$8.62 million\u003c\/strong\u003e (down from \u003cstrong\u003e\\$16.15 million\u003c\/strong\u003e the prior year) showed improving cash burn efficiency leading into the merger.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e Showing a significant reduction in quarterly loss is a positive signal for a pre-merger biotech.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e Cost control measures are imitable, but the specific trajectory of loss reduction is unique to their operations.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e The organizational streamlining in 2024\/2025 directly contributed to this improved financial metric.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e Temporary; this metric is historical and superseded by the post-merger balance sheet.\u003c\/p\u003e\n\u003cp\u003eFinance: Pro-forma cash runway analysis for ImageneBio incorporating the \u003cstrong\u003e\\$75 million\u003c\/strong\u003e PIPE, assuming the PIPE closes on the hypothetical 'next Tuesday' following the Q1 2025 report date (May 8, 2025).\u003c\/p\u003e\n\u003cp\u003eThe Q1 2025 cash balance for Ikena Oncology is not explicitly available in the latest search results; therefore, the pro-forma calculation will use the last confirmed balance sheet figure from Q1 2024 as the closest available pre-merger starting point for context, alongside the Q1 2025 operating loss.\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003ctd\u003eMetric\u003c\/td\u003e\n\u003ctd\u003eIKNA Q1 2025 (Actual)\u003c\/td\u003e\n\u003ctd\u003eIKNA Q1 2024 (Reference)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eNet Loss (USD)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e\\$8.62 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e\\$16.15 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCash, Cash Equivalents, \u0026amp; Marketable Securities (USD)\u003c\/td\u003e\n\u003ctd\u003eNot Explicitly Found\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e\\$157.3 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eBasic Loss Per Share (USD)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e\\$0.18\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e\\$0.33\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003ePro-forma Cash Runway Analysis for ImageneBio (Hypothetical Post-Merger Scenario):\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eAssumed Starting Cash Balance (Post-PIPE, Pre-Merger Operations): \u003cstrong\u003e\\$157.3 million\u003c\/strong\u003e (Using Q1 2024 closing balance as the closest confirmed balance sheet figure to the Q1 2025 snapshot).\u003c\/li\u003e\n\u003cli\u003eHypothetical Financing Inflow (PIPE): \u003cstrong\u003e\\$75.0 million\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003ePro-forma Cash Injection: \u003cstrong\u003e\\$157.3 million\u003c\/strong\u003e + \u003cstrong\u003e\\$75.0 million\u003c\/strong\u003e = \u003cstrong\u003e\\$232.3 million\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eEstimated Quarterly Net Cash Burn (Based on Q1 2025 Loss): \u003cstrong\u003e\\$8.62 million\u003c\/strong\u003e per quarter.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eEstimated Pro-Forma Cash Runway:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eRunway in Quarters: \u003cstrong\u003e\\$232.3 million\u003c\/strong\u003e \/ \u003cstrong\u003e\\$8.62 million\u003c\/strong\u003e $\\approx$ \u003cstrong\u003e26.95 quarters\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eRunway in Years: \u003cstrong\u003e26.95 quarters\u003c\/strong\u003e \/ 4 $\\approx$ \u003cstrong\u003e6.74 years\u003c\/strong\u003e.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eThe merger with Inmagene was completed on \u003cstrong\u003eJuly 28, 2025\u003c\/strong\u003e.\u003c\/p\u003e","brand":"dcf.fm","offers":[{"title":"Default Title","offer_id":45516185862293,"sku":"ikna-vrio-analysis","price":7.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0630\/5189\/0837\/files\/ikna-vrio-analysis.png?v=1740183691","url":"https:\/\/dcf-analysis.com\/products\/ikna-vrio-analysis","provider":"AI-Powered Discounted Cash Flow Model Templates","version":"1.0","type":"link"}